Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY REPORTS Q2 2025 AUCATZYL NET PRODUCT REVENUE OF $20.9 MILLION AND $29.9 FOR THE FIRST SIX MONTHS OF 2025 COMPANY RECENTLY RECEIVED CONDITIONAL MARKETING AUTHORIZATION FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AND CONDITIONAL EUROPEAN MARKETING AUTHORIZATION FROM THE EUROPEAN COMMISSION (EC) FOR AUCATZYL FOLLOW UP DATA FROM THE FELIX TRIAL DEMONSTRATING OBE-CEL'S POTENTIAL FOR LONG-TERM REMISSION IN R/R B-ALL PRESENTED AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS COMPANY IS ON TRACK TO INITIATE PHASE 2 PIVOTAL CLINICAL TRIAL IN LUPUS NEPHRITIS (LN) AND PHASE 1 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) BY YEAR-END 2025 CONFERENCE CALL TO BE HELD TODAY AT 08:30 AM EDT/13:30 PM BST: CONFERENCE CALL PARTICIPANTS SHOULD PRE-REGISTER USING THE LINK AT THE BOTTOM OF THIS PRESS RELEASE LONDON AND GAITHERSBURG, MD., AUG. 12, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES ITS OPERATIONAL AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

AUTOLUS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

LONDON AND GAITHERSBURG, MD., JULY 24, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES THAT IT WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS BEFORE OPEN OF U.S. MARKETS ON TUESDAY, AUGUST 12, 2025.

AUTOLUS THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2025

APPROVAL IS BASED ON FELIX CLINICAL TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WITH R/R B-ALL, DEMONSTRATING HIGH AND DURABLE RESPONSE RATES AND LOW TOXICITY EC APPROVAL FOLLOWS POSITIVE CHMP OPINION, MHRA CONDITIONAL MARKETING AUTHORIZATION AND FDA APPROVAL LONDON AND GAITHERSBURG, MD., JULY 21, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, ANNOUNCES TODAY THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR AUCATZYL (OBECABTAGENE AUTOLEUCEL OR OBE-CEL) FOR THE TREATMENT OF ADULT PATIENTS, 26+, WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL).

AUTOLUS THERAPEUTICS' CAR T THERAPY AUCATZYL (OBECABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)

LONDON & GAITHERSBURG, MD., JULY 15, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 360,550 SHARES OF ITS COMMON STOCK TO 60 EMPLOYEES PURSUANT TO THE COMPANY'S 2025 INDUCEMENT PLAN. THE STOCK OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE INDIVIDUAL BECOMING AN EMPLOYEE OF AUTOLUS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MEDIAN DURATION OF RESPONSE IN FELIX STUDY NOW 42.6 MONTHS AFTER AN ADDITIONAL 11 MONTHS OF FOLLOW UP MORE THAN HALF OF PATIENTS STILL IN REMISSION AT 24 MONTHS 38% OF ONGOING RESPONDERS DID NOT RECEIVE ANY SUBSEQUENT THERAPY BY MONTH 33 RESULTS SUGGEST A PROPORTION OF PATIENTS WITH R/R B-ALL MAY NOT NEED FURTHER THERAPY FOLLOWING TREATMENT WITH OBE-CEL LONDON, JUNE 12, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES UPDATED LONG TERM DATA (UP TO APPROXIMATELY THREE YEARS OF FOLLOW UP) FROM THE FELIX STUDY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL), TO BE PRESENTED IN AN ORAL PRESENTATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS BETWEEN JUNE 12-15, 2025, IN MILAN, ITALY. AUTOLUS WILL ALSO PRESENT AN ADDITIONAL ORAL AND POSTER PRESENTATION, THE DETAILS OF WHICH ARE INCLUDED BELOW.

AUTOLUS THERAPEUTICS PRESENTS LONG-TERM FOLLOW UP FROM THE FELIX STUDY DEMONSTRATING OBE-CEL'S POTENTIAL FOR LONG-TERM REMISSION IN R/R B-ALL AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS

LONDON, MAY 29, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE COMPANY WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES. WILLIAM BLAIR 45 TH ANNUAL GROWTH STOCK CONFERENCE MANAGEMENT TO HOST INVESTOR MEETINGSDATE: JUNE 3, 2025LOCATION: CHICAGO, IL JEFFERIES GLOBAL HEALTHCARE CONFERENCE FIRESIDE CHAT PRESENTATIONDATE AND TIME: JUNE 5, 2025; 3:10PM EDT / 20:10PM BSTLOCATION: NEW YORK, NYPRESENTER: CHIEF EXECUTIVE OFFICER DR. CHRISTIAN ITIN GOLDMAN SACHS 46 TH ANNUAL GLOBAL HEALTHCARE CONFERENCE FIRESIDE CHAT PRESENTATIONDATE AND TIME: JUNE 11, 2025; 1:20PM EDT / 18:20 BSTLOCATION: MIAMI, FLPRESENTER: CHIEF FINANCIAL OFFICER ROB DOLSKI A WEBCAST OF THE FIRESIDE CHATS WILL BE AVAILABLE ON THE EVENTS PAGE IN THE INVESTOR RELATIONS & MEDIA SECTION OF THE COMPANY'S WEBSITE ATHTTPS://WWW.AUTOLUS.COM/INVESTOR-RELATIONS-MEDIA/EVENTS/.

AUTOLUS THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

AUTOLUS THERAPEUTICS ANNOUNCES POSITIVE CHMP OPINION FOR OBECABTAGENE AUTOLEUCEL FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-ALL

AUTOLUS THERAPEUTICS ANNOUNCES POSITIVE CHMP OPINION FOR OBECABTAGENE AUTOLEUCEL FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)

LONDON, MAY 14, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THE ONLINE PUBLICATION OF THREE ABSTRACTS SUBMITTED TO THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS, TO BE HELD JUNE 12-15, 2025, MILAN, ITALY. AUTOLUS WILL HAVE TWO ORAL AND ONE POSTER PRESENTATION, WHICH INCLUDES UPDATED FOLLOW UP FROM THE FELIX STUDY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL).

AUTOLUS THERAPEUTICS PRESENTS CLINICAL DATA UPDATES AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS

COMPANY REPORTS Q1 2025 AUCATZYL NET PRODUCT REVENUE OF $9.0 MILLION U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR AUCATZYL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) ENCOURAGING PRELIMINARY DATA REPORTED IN PHASE 1 CARLYSLE TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE);PLANNED PHASE 2 PIVOTAL CLINICAL TRIAL IN LUPUS NEPHRITIS (LN) AND PHASE 1 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) INITIATING BEFORE YEAR-END 2025 CONFERENCE CALL TO BE HELD TODAY AT 08:30 AM EDT/13:30 PM GMT: CONFERENCE CALL PARTICIPANTS SHOULD PRE-REGISTER USING THE LINK AT THE BOTTOM OF THIS PRESS RELEASE LONDON, MAY 08, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES ITS OPERATIONAL AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. WE HAD A GREAT FIRST QUARTER OF LAUNCH AND ARE HIGHLY ENCOURAGED BY PHYSICIAN ENTHUSIASM FOR AUCATZYL IN THE U.S. WE BELIEVE THIS SPEAKS TO THE PRODUCT PROFILE AND SIGNIFICANT UNMET NEED FOR PATIENTS, SAID DR. CHRISTIAN ITIN, CHIEF EXECUTIVE OFFICER OF AUTOLUS.

AUTOLUS THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

AUTOLUS THERAPEUTICS ANNOUNCES LICENSE OF AUCATZYL (OBECABTAGENE AUTOLEUCEL) ISSUED BY UK MHRA FOR ADULT PATIENTS ( 18 YEARS) WITH RELAPSED OR REFRACTORY

AUTOLUS THERAPEUTICS ANNOUNCES LICENSE OF AUCATZYL (OBECABTAGENE AUTOLEUCEL) ISSUED BY UK MHRA FOR ADULT PATIENTS ( 18 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)(1)

COMPANY OUTLINED POTENTIAL FOR VALUE CREATION DRIVEN BY OBE-CEL ACROSS MULTIPLE B CELL DRIVEN MALIGNANCIES AND AUTOIMMUNE DISEASES, INCLUDING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), LUPUS NEPHRITIS (LN) AND MULTIPLE SCLEROSIS (MS) PRELIMINARY DATA IN INITIAL SIX PATIENT COHORT TREATED IN PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SUPPORT PROGRESSING OBE-CEL INTO A PLANNED PHASE 2 PIVOTAL STUDY IN LUPUS NEPHRITIS; FIRST PATIENT EXPECTED TO BE DOSED IN PHASE 2 TRIAL BY YEAR-END 2025 COMPANY PLANS TO ADVANCE OBE-CEL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS); FIRST PATIENT EXPECTED TO BE DOSED IN PHASE 1 TRIAL BY YEAR-END 2025 LONDON, APRIL 23, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY PRESENTED UPDATES ON ITS DEVELOPMENT PIPELINE AND PLANS FOR EXPANSION IN AUTOIMMUNE DISEASES AT AN R&D INVESTOR EVENT. THE COMPANY PRESENTED DEVELOPMENT PLANS TO EXPAND THE OBE-CEL OPPORTUNITY INTO AUTOIMMUNE DISEASE, INCLUDING A POTENTIAL REGISTRATIONAL PATH FOR OBE-CEL IN LN.

Autolus Therapeutics plc

AUTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Autolus Therapeutics plc

AUTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AUTL